The Time is Now

Paul, Reid
September 2010
Pharmaceutical Representative;Sep2010, Vol. 40 Issue 9, p5
The author reflects on the announcement of pharmaceutical company GlaxoSmithKline (GSK) to abandon prescription sales targets when determining representative (rep) bonuses in the U.S. He believes that the decision of GSK will certainly affect the compensation of sales representatives. He stresses that it is unfair to hold reps to a sales quota when it necessitates a physician to write a prescription, a patient to fill the prescription as well as a pharmacy to fill the prescription as written.


Related Articles

  • Attention, raise-seekers: Read this before asking.  // Sales Insider;1/27/2010, Vol. 4 Issue 79, p2 

    The article presents a story of how a sales personnel seeking a raise learned from a recently promoted colleague on how to do their work.

  • Knowing how your competitor sells can help you sell more. Gitomer, Jeffrey // Budapest Business Journal;6/17/2002, Vol. 10 Issue 28, p20 

    Presents tips for salesman in order to outsell the competition. Counterpart's sales process; Compensation of a sales personnel; Maintenance of competitive intelligence.

  • LETTER TO THE EDITOR. Hollingsworth, Terry // Furniture/Today;3/17/2014, Vol. 38 Issue 29, p35 

    A letter to the editor is presented in response to the article concerning the compensation of sales representatives.

  • Greed. Medcalf, Graham // NZ Marketing Magazine;Dec2005, Vol. 24 Issue 11, p2 

    The article highlights the feeling of joy the author had upon learning that marketers in New Zealand have realistic attitude about their salary based on the 2005 Hudson Salary Survey. It is good to know that marketers are idealists not materialists. This fact is important particularly in the...

  • GlaxoSmithKline Tracks R&D Performance. Ritter, Amy // BioPharm International;Mar2012, Vol. 25 Issue 3, p13 

    The article reports that the 12% up return from 11% in 2011 was tracked by GlaxoSmithKline (GSK) in its research and development (R&D) performance in the fourth quarter and full year 2011 earnings report released on February 7, 2012.

  • Target Practice.  // Pharmaceutical Representative;Sep2010, Vol. 40 Issue 9, p14 

    The article focuses on the impact of the move of the pharmaceutical company GlaxoSmithKline (GSK) to abandon prescription sales target when determining pharmaceutical sales representative bonuses on its sales force in the U.S. It notes that bonuses for most members of the GSK's sales force will...

  • How Doctors Rate Reps. Leonhauser, Melissa // Pharmaceutical Representative;Feb2011, Vol. 41 Issue 2, p26 

    The article presents the result of the survey participated by office-based physicians from 27 specialties in the U.S. concerning the performance of sales representatives and companies that employed them. It states that there is a declining number of sales reps employed by top 40 pharmaceutical...

  • GSK citing primary care glut, cuts sales force 12%. Vecchione, Anthony // Medical Marketing & Media;Dec2008, Vol. 43 Issue 12, p8 

    The article reports that GlaxoSmithkline (GSK) announced that it will reduce its sales personnel by 12 percent to 7500 down from 8,500. The company is planning to slash 1,800 jobs resulting in a total of 1,000 layoffs. The decision has been taken in the wake of a rash of sales force cuts by...

  • Advair sales strategy shifting in 2007. Iskowitz, Marc // Medical Marketing & Media;Feb2007, Vol. 42 Issue 2, p26 

    The article announces the formation of a new Glaxosmithkline's sales force to market Advair, a long-acting beta2 for treatment of chronic obstructive pulmonary disease (COPD). Glaxosmithkline's president David Stout announced the formation of the new sales force which will also allow existing...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics